If you have been reading about reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
4-Methyl sterols are intermediates in the biosynthesis of 4-desmethyl sterols and are known to accumulate under anaerobic conditions. The synthesis of dinosterol begins with the cyclization of squalene to lanosterol, but then diverges from cholesterol biosynthesis. The biosynthesis of dinosterol's side chain has been investigated in dinoflagellates using methionine-[CD3]. The sequence of side-chain alkylations is thought to be initiated by the formation of 4α,24-dimethyl-5α-cholest-24(28)-en-3β-ol, followed by reduction to 4α,24-dimethyl-5α-cholestan-3β-ol, then introduction of the Δ22-double bond to form 4α,24-dimethyl-5α-cholest-22E-en-3β-ol and then methylation at C-23 to form 4α23,24-trimethyl- 5α-cholest-22E-en-3β-ol (dinosterol).
=== Parts and cleavages === Transcript variant 1 of PIDD1 mRNA in humans, produces a full-length PIDD1 protein consisting of 910 amino acids, with a molecular weight of about 100 kDa. This protein can be broken down into three parts: a 48 kDa N-terminal fragment called PIDD-N, and two C-terminal fragments, PIDD-C (51 kDa) and PIDD-CC (37 kDa). These cleavages occur at positions S446 and S588 through an autoproteolytic process that resembles proteins like inteins or nucleoporin Nup98 undergo self-cleavage. These proteins contain a conserved HSF tripeptide framework that enables a hydrophilic attack of the hydroxyl-group within the serine residue on the preceding peptide bond, converting it into an ester bond that is susceptible to cleavage by an additional nucleophile. The cleavage of full-length PIDD1 (FL-PIDD1) into PIDD-C or PIDD-CC seems to occur constitutively, meaning it happens regularly, which makes FL-PIDD1 levels remain low even when p53 is activated. However, the observation that PIDD-C accumulates before PIDD-CC in response to DNA damage supports the idea that PIDD-C is the primary form generated from FL-PIDD1.
Biko's given name "Bantu" means "people" in IsiXhosa; Biko interpreted this in terms of the saying "Umntu ngumntu ngabantu" ("a person is a person by means of other people"). As a child he was nicknamed "Goofy" and "Xwaku-Xwaku", the latter a reference to his unkempt appearance. He was raised in his family's Anglican Christian faith. In 1950, when Biko was four, his father fell ill, was hospitalised in St. Matthew's Hospital, Keiskammahoek, and died, making the family dependent on his mother's income. Biko spent two years at St. Andrews Primary School and four at Charles Morgan Higher Primary School, both in Ginsberg. Regarded as a particularly intelligent pupil, he was allowed to skip a year. In 1963 he transferred to the Forbes Grant Secondary School in the township. Biko excelled at maths and English and topped the class in his exams. In 1964 the Ginsberg community offered him a bursary to join his brother Khaya as a student at Lovedale, a prestigious boarding school in Alice, Eastern Cape. Within three months of Steve's arrival, Khaya was accused of having connections to Poqo, the armed wing of the Pan Africanist Congress (PAC), an African nationalist group which the government had banned. Both Khaya and Steve were arrested and interrogated by the police; the former was convicted, then acquitted on appeal. No clear evidence of Steve's connection to Poqo was presented, but he was expelled from Lovedale. Commenting later on this situation, he stated: "I began to develop an attitude which was much more directed at authority than at anything else.
Sources: en.wikipedia.org
The most famous of these took place during the Battle of Smolensk under the command of Lev Dovator, whose 3rd Cavalry Corps consisted of the 50th and 53rd Cavalry divisions from the Kuban and Terek Cossacks mobilised from the Northern Caucasus. The raid in ten days covered 300 km and destroyed the hinterlands of the 9th German Army before successfully breaking out. Whilst units under the command of General Pavel Belov, the 2nd Cavalry Corps of Don, Kuban and Stavropol Cossacks spearheaded the counter-attack onto the right flank of the 6th German Army, delaying its advance towards Moscow. The high professionalism that the Cossacks under Dovator and Belov (both generals would later be granted the title Hero of the Soviet Union and their units raised to a Guards (elite) status) ensured that many new units would be formed. The Germans during the whole war only managed to form two Cossack Corps, while the Red Army in 1942 alone had 17. Many of the newly formed units were filled with ethnically Cossack volunteers. The Kuban Cossacks were allocated to the 10th, 12th and 13th Corps. However, the most famous Kuban Cossack unit was the 17th Cossack Corps under the command of general Nikolay Kirichenko. During one particular attack, Cossacks killed up to 1,800 enemy soldiers and officers, took 300 prisoners, and seized 18 artillery pieces and 25 mortars. The 5th and 9th Romanian Cavalry divisions fled in panic, and the 198th German Infantry division hastily departed with large losses to the left bank of the river Ei.
==== Animal substances ==== Some animal parts used include cow gallstones, hornet nests, leeches, and scorpion. Other examples of animal parts include horn of the antelope or buffalo, deer antlers, testicles and penis bone of the dog, and snake bile. Some TCM textbooks still recommend preparations containing animal tissues, but there has been little research to justify the claimed clinical efficacy of many TCM animal products. 968+8956
However, patients with high tumor accumulation and multiple lesions seemed to benefit from 90Y-DOTATOC, while patients with low tumor burden, solitary lesions and extra-hepatic disease experienced more favorable outcome on 177Lu-DOTATOC. There were significantly fewer cases of transitory hematotoxicity in the 177Lu-DOTATOC group compared with the 90Y-DOTATOC group (1.4% versus 10.1%, p=0.001). The randomized controlled phase III Neuroendocrine Tumors Therapy (NETTER-1) trial evaluated the efficacy and safety of 177Lu-DOTATATE as compared with high-dose octreotide long-acting repeatable (LAR) in patients with advanced progressive somatostatin-receptor positive midgut neuroendocrine tumors. Patients were randomly assigned to receive either 177Lu-DOTATATE and octreotide LAR at a dose of 30 mg every four weeks for symptom control (n=116) or to only receive octreotide LAR at a dose of 60 mg every four weeks (n=113, control group). In total, 200 out of the 231 patients entered long-term follow-up. Final overall survival in the intention-to-treat population was median 48.0 months in the 177Lu-DOTATATE group versus median 36.3 months in the control group (p=0.30). In other words, there was numerical difference of 11.7 months, not reaching statistical significance. 177Lu-DOTATATE was associated with limited acute toxic effects. In neuroendocrine tumor patients with advanced well-differentiated disease and progression on somatostatin analogs, 177Lu-DOTATATE is likely to reduce the risk of disease progression and be associated with quality-of-life benefits.
The vagina is attached to the pelvic walls by endopelvic fascia. The peritoneum is the external layer of skin that covers the fascia. This tissue provides additional support to the pelvic floor. The endopelvic fascia is one continuous sheet of tissue and varies in thickness. It permits some shifting of the pelvic structures. The fascia contains elastic collagen fibers in a 'mesh-like' structure. The fascia also contains fibroblasts, smooth muscle, and vascular vessels. The cardinal ligament supports the apex of the vagina and derives some of its strength from vascular tissue. The endopelvic fascia attaches to the lateral pelvic wall via the arcus tendineus.
Sources: en.wikipedia.org
=== Sources === Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. (2003). Fitzpatrick's Dermatology in General Medicine (6th ed.). McGraw-Hill. ISBN 978-0-07-138076-8. James W, Berger T, Elston D (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. ISBN 978-0-7216-2921-6. Rapini RP, Bolognia JL, Jorizzo JL (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
Australia contributed a Naval Task Group, which formed part of the multi-national fleet in the Persian Gulf and Gulf of Oman, under Operation Damask. Medical teams were deployed aboard a US hospital ship, and a naval clearance diving team took part in de-mining Kuwait's port facilities following the end of combat operations. Australian forces experienced a number of incidents in the first number of weeks of the Desert Storm Campaign including the detection of significant air threats from Iraq as a part of the outer perimeter of Battle Force Zulu; the detection of free sea floating mines and assistance to the aircraft carrier USS Midway. The Australian Task Force was also placed at great risk with regard to the sea mine threat, with HMAS Brisbane narrowly avoiding a mine. The Australians played a significant role in enforcing the sanctions put in place against Iraq following Kuwait's invasion. Following the war's end, Australia deployed a medical unit on Operation Habitat to northern Iraq as part of Operation Provide Comfort.
=== Uptake === Tau protein has been found in the extracellular environment including Cerebrospinal fluid (CSF) and Interstitial fluid (ISF) under physiological and pathological conditions. Low-density lipoprotein receptor-related protein 1 (LRP1) has been shown as the receptor for Tau internalization into cells. However, studying Tau uptake in human neurons revealed that physiological Tau monomers mainly use LRP1 for internalization, while the uptake of pathological Tau aggregates depend on heparan sulfate proteoglycans.
It is a functional and structural analog of other psychedelic tryptamines such as 4-AcO-DMT (O-acetylpsilocin), psilocybin (4-PO-DMT), psilocin (4-HO-DMT), O-methylbufotenin (5-MeO-DMT), and bufotenin (5-HO-DMT). Parts of the structure of DMT occur within some important biomolecules like serotonin and melatonin, making them structural analogues of DMT. DMT exhibits broad and variable binding affinities across numerous receptors, showing its strongest interactions with serotonin receptors, especially 5-HT2A, 5-HT1A, and 5-HT2C, which are believed to mediate its psychedelic effects. Endogenous DMT, a psychedelic compound, is naturally produced in mammals, with evidence showing its synthesis and presence in brain and body tissues, though its exact roles and origins remain debated. DMT is internationally illegal without authorization, with most countries banning its possession and trade, though some allow religious use of ayahuasca, a DMT-containing decoction. Short-acting psychedelics like DMT are considered scalable alternatives to longer-acting drugs like psilocybin for potential clinical use. DMT is currently undergoing clinical trials for treatment-resistant depression.
== Structure and classification == Aminopeptidases are a diverse group of enzymes that play crucial roles in various biological processes, including protein digestion, cell growth, and immune response. They are classified based on their substrate specificity (strength of binding) and catalytic mechanism (means of catalyzing their reaction) into two main categories: metalloaminopeptidases and cysteine aminopeptidases. Metalloaminopeptidases use a metal ion to perform their function, and cysteine aminopeptidases use a particular cysteine amino acid. The structure of aminopeptidases varies depending on the specific enzyme, but they generally consist of a catalytic domain where the catalysis occurs and additional domains that contribute to target recognition and regulation of their functions. For instance, Aminopeptidase N (APN), a type II metalloprotease, consists of 967 amino acids with a short N-terminal cytoplasmic domain in the cytoplasm, a single transmembrane part reaching through the cellular membrane, and a large cellular ectodomain sticking out of the cell containing the active site.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.